171 related articles for article (PubMed ID: 31844142)
1. A genome-scale CRISPR/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine.
Masoudi M; Seki M; Yazdanparast R; Yachie N; Aburatani H
Sci Rep; 2019 Dec; 9(1):19188. PubMed ID: 31844142
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of the herbal mixture C5E on gemcitabine treatment in PANC‑1 cells.
Pak PJ; Lee DG; Sung JH; Jung SH; Han TY; Park SH; Chung N
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760105
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.
Guo Y; Ziesch A; Hocke S; Kampmann E; Ochs S; De Toni EN; Göke B; Gallmeier E
J Cell Mol Med; 2015 Feb; 19(2):340-50. PubMed ID: 25331547
[TBL] [Abstract][Full Text] [Related]
4. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Bhattacharjee V; Zhou Y; Yen TJ
Cell Cycle; 2014; 13(24):3839-56. PubMed ID: 25558828
[TBL] [Abstract][Full Text] [Related]
5. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Sarr A; Bré J; Um IH; Chan TH; Mullen P; Harrison DJ; Reynolds PA
Sci Rep; 2019 May; 9(1):7643. PubMed ID: 31113993
[TBL] [Abstract][Full Text] [Related]
6. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
7. Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
Ge J; Ge C
Virchows Arch; 2019 Jan; 474(1):59-69. PubMed ID: 30267303
[TBL] [Abstract][Full Text] [Related]
8. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
9. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
10. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y
Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914
[TBL] [Abstract][Full Text] [Related]
12. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
Liau SS; Ashley SW; Whang EE
J Gastrointest Surg; 2006 Nov; 10(9):1254-62; discussion 1263. PubMed ID: 17114012
[TBL] [Abstract][Full Text] [Related]
14. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
Hamed SS; Straubinger RM; Jusko WJ
Cancer Chemother Pharmacol; 2013 Sep; 72(3):553-63. PubMed ID: 23835677
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells.
You L; Chang D; Du HZ; Zhao YP
Biochem Biophys Res Commun; 2011 Apr; 407(1):1-6. PubMed ID: 21316338
[TBL] [Abstract][Full Text] [Related]
18. MiR-760 enhances sensitivity of pancreatic cancer cells to gemcitabine through modulating Integrin β1.
Yang D; Hu Z; Xu J; Tang Y; Wang Y; Cai Q; Zhu Z
Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31693728
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
